In the 2009/2010 financial year, 795,892 units of red blood cells (RBC) were issued to public and private hospitals throughout Australia under the national supply plan for RBCs. The corresponding national budget approved by Australian health ministers for the supply of fresh blood products and plasma was $456.1 million 1 . Over time, the issuance and usage of blood products has increased. A significant proportion of this represents an underlying increase in hospital activity, patient acuity and survival with disease 2 .
Concurrently, a wider understanding of the risk profile associated with the use of blood products is now emerging. The well-described infectious risk associated with transfusion of blood products represents only a proportion of the true risk, with non-infectious complications such as transfusionrelated acute lung injury and transfusion-associated circulatory overload now among the leading causes of reported transfusion-related deaths 3 . Additionally, case-controlled studies of medical, surgical and intensive care unit cohorts suggest an association SUMMARy The aim of this paper is to describe a linked patient blood management (PBM) data system and to demonstrate its usefulness by presenting the blood usage data obtained.
Our existing datasets already collected much of the required information in relation to PBM. However, these datasets were not linked. A patient identifier was used to link the Patient Administration System with the Laboratory Information System. Data linkage was achieved by linking the Laboratory Information System with the Patient Administration System records where blood transfusion or laboratory result date/time fell between admission and discharge date/time. The two datasets were then consolidated into the PBM data system.
Blood usage data obtained from the system showed that between August 2008 and July 2009 there were 59,627 patient completed separations in the pilot hospital. Of the total transfused units, 62% were red blood cells (RBC), followed by fresh frozen plasma (22%), cryoprecipitate (9%) and platelets (8%). Around 50% of RBC transfusions were administered to patients >70 years of age. General medicine represented 21% of RBC usage, followed by haematology (19%), orthopaedics (17%) and general surgery (16%). Patients with 100 g/l pre-transfusion haemoglobin received 9% of RBC transfusions and patients with 71-100 g/l pre-transfusion haemoglobin received 73% of RBC transfusions. The post-transfusion haemoglobin in RBC transfusions exceeded 100 g/l in 33% of patients.
Databases were successfully linked to produce a powerful tool to monitor blood utilisation and transfusion practices within a pilot PBM program. This will facilitate effective targeting of PBM strategies and ongoing monitoring of their impact. between unnecessary transfusion and poorer patient outcomes [4] [5] [6] [7] . In certain clinical situations where there is acute haemorrhage and coagulopathies, the use of blood products has life-saving potential 8 . However, there is increasing evidence that inappropriate blood transfusions may add to the burden of risks with increased morbidity and mortality 5 . There is therefore a need to review transfusion practice in order to identify opportunities for improved patient outcomes and to reduce costs.
The risks of transfusions are recognised in the National Health and Medical Research Council/ Australasian Society of Blood Transfusion guidelines of 2002 9 and in more recent patient blood management (PBM) guidelines. Within Western Australia (WA), there is considerable variation in transfusion practice and compliance with current guidelines. It seems timely to examine current practice and consider approaches to inform prescribing, enhance compliance with evidence-based and consensus best practice and implement pre-emptive PBM strategies to improve patient outcomes.
In 2008, WA Health initiated a jurisdictional approach to PBM 11 . Western Australian hospitals are being encouraged to shift from 'transfusion' as a default setting to a patient-oriented approach in blood management. PBM aims to improve clinical outcomes by avoiding unnecessary exposure to blood components and to optimise the use of donor blood and reduce transfusion-associated risks. These aims are articulated through the "three pillars" of PBM: 1) optimising the patient's blood volume and red cell mass; 2) minimising blood loss; and 3) optimising the patient's tolerance of anaemia 12 . The approach recognises that while in some situations blood transfusions may be beneficial, the risk-benefit profile of transfusion must be assessed on an individual patient basis. PBM therefore requires an integrated perioperative multidisciplinary, multimodal team approach to optimising the patient's own red cell mass (by addressing underlying anaemia/iron deficiency, minimising intraoperative blood loss and optimising physiological tolerance of anaemia).
A key element in effecting change is obtaining data on current prescribing practice; a mechanism that permits tracking of the way blood products are used and measures the incidence of inappropriate blood transfusions enables feedback on individual practice and outcomes, benchmarking one's practice against peers and identifying target groups for focused interventions. It encourages the process where hospital departments can review an individual consultant's performance, meaning that the results are interpreted by professionals who are most concerned with or related to the outcome of patient care 13 . At the commencement of the WA PBM program in 2008, no automated jurisdictional system linking transfusion and clinical data was identified in WA or in other jurisdictions.
The aim of this paper is to describe a linked PBM system and to demonstrate its usefulness by presenting the blood usage data obtained from the system for the pilot hospital. The paper also discusses the opportunities provided and limitations of such a system.
METHODS

Identification of information silos
System feasibility, analysis and design for the PBM data system were conducted by looking at the reporting requirements of the PBM program in relation to the available data sources. After deciphering the content of the current hospital information systems used within WA Health (Table 1) , the open patient administrative system (PAS) was found to already collect much of the required patient administration information, whereas the laboratory information systems (LIS) ultra and transfusion medicine datasets were the data sources for blood transfusions and laboratory results. These datasets were sufficiently refined to enable interrogation at the levels required. A single database was then created to collate and link hospital admission and transfusion data from existing databases and issue reports of blood usage in WA.
Data linkage
Across the public metropolitan hospitals, a single unique patient identifier, the unit medical record number was used. There was no direct link between the patient admission records in the PAS dataset and laboratory results and blood transfusions in the LIS datasets. Therefore, the unit medical record number was used in the LIS datasets to track allocation of product to its recipient. Only actual blood transfusions (excluding wastage) and laboratory results were linked with PAS records where blood transfusion or laboratory result date/time fell between admission and discharge date/time ( Figure 1 ). Although rare, Table 1 Databases interrogated for development of the patient blood management data system
Patient demographic and clinical databases
Open patient administration system Hospital morbidity data system Emergency department information system Theatre management system
Laboratory information systems
Transfusion medicine dataset Ultra dataset it was possible for a patient to have more than one overlapping admission in the PAS. Such records were flagged and then subsequently removed to prevent the same blood transfusion event being counted against multiple separations. The two datasets were consolidated into the PBM data system for further processing and interrogation.
Ethics
A detailed ethics application was submitted to the Hospital Ethics Committee. After the review, the investigators were informed that ethics approval was not required as the study was for data audit purposes (dated 20/12/2012). To disseminate the data to individual clinicians and organisations that are not covered by the ethics waiver, a formal data access and governance structure has been put in place.
Data analysis
Specific analyses of interest included the proportion of separations in which a patient received a transfusion, key users of blood products within the pilot hospital, the key diagnostic and procedural groups associated with blood product usage and the pre and post-transfusion haemoglobin (Hb). The pilot hospital formally commenced a multidisciplinary multimodal PBM program in August 2009. Hence, the 12-month interval spanning 1 August 2008 to 31 July 2009 forms the basis of this report and provides a baseline for identifying targets for intervention and overall assessment of the impact of a formal PBM program. However, a description of the multiple strategies implemented as part of the program is beyond the scope of this paper.
Pre-transfusion Hb was obtained as the latest Hb result value before the transfusion date and time from laboratory results in the LIS by going back as far as 30 days. Post-transfusion Hb value was obtained as the first Hb result up to three days after the index transfusion event. Transfusion events are described as the total number of units transfused within 24 hours. The clinical areas prescribing blood products were also examined.
RESULTS
Demographics of blood transfusions
Between 1 August 2008 and 31 July 2009, around 98% of transfusion events were linked with their clinical details ( Figure 1 ). There were 59,627 patient completed separations in the pilot hospital ( Figure  2 ). Transfusion of RBCs represented the majority of transfused units (62%), followed by fresh frozen plasma (22%), cryoprecipitate (9%) and platelets (8%). Further breakdown of fresh blood products usage is given in Table 2 . Table 3 characterises the recipients of RBC units by age. In total, patients >70 years represented 31% in this hospital. Correspondingly, the majority of RBC units were administered to patients >70 years. The proportion of patient separations and blood use for both males and females >70 years were similar to that of the total proportions. The analysis, however, suggests that there are significant differences between male and female patients for proportion of blood use in different age groups. Compared to male patients, female patients 21-40 years received more blood, whereas male patients 61-80 years received more blood. Figure 3 summarises the key users of RBC units. During the study period, general medicine represented 21% of RBC usage, followed by haematology (19%), orthopaedics (17%) and general surgery (16%). These account for 73% of the total RBC use but only represent 28% of total patient activity. In this analysis, the specialty is defined as that of the consultant at the time of discharge. Figure 4 presents blood usage by 24 hours transfusion event and whole of patient stay (separation) at the hospital. Almost half of the blood transfusion episodes and transfusion separations required two units of RBCs. The proportion of single unit transfusion events was 39% compared to only 15% of patient transfusion separation being single unit separation.
Patterns of red cell use
Pre and post-transfusion haemoglobin
Patients with 100 g/l pre-transfusion Hb received 9% of RBC transfusions and patients with 71-100 g/l pre-transfusion Hb received 73% of RBC transfusions ( Figure 5 ). The first recorded Hb level noted following a transfusion of RBC units exceeded 100 g/l in 33% of patients. 
DISCUSSION
The detailed blood usage data highlights the usefulness of our linked PBM data system in effectively monitoring the use of blood products by key users, clinical diagnoses, and procedures associated with transfusions. The PBM data system also presents additional opportunities to link and benchmark transfusion practice between departments, hospitals and clinicians. Coupled together, these insights will assist in better designing targeted approaches to PBM. The data obtained from the PBM system was found to be very operational while assessing hospital and department compliance against the 2001 national guidelines around blood use 9 . A total of 82% of transfusions were administered to patients with last recorded Hb before transfusion exceeding 70 g/l and only 9% to patients with last recorded Hb exceeding 100 g/l. Consideration of these results must be prefaced by the observation that in some environments (e.g. acute care areas, theatre, emergency departments) clinicians may transfuse in response to results obtained by point of care devices (e.g. HemoCue, thromboelastometry and arterial blood gas machines). In Western Australian public hospitals, the results attained from such devices are not routinely captured in electronic databases. In contrast, blood tests performed in the pathology laboratories are captured in both the LIS and the PAS. Thus, reference to the last noted Hb level in the LIS may not provide an accurate picture of the Hb, or the clinical context, leading to the decision to transfuse.
The first recorded Hb level following a transfusion of RBCs exceeded 100 g/l in 33% of patients. Noting that the majority of patients were transfused with either one or two units of RBCs and in keeping with the observation that the majority of transfused patients had pre-transfusion Hb exceeding 70 g/l, this implies that a proportion of transfused patients were not actively bleeding at the time of transfusion. The PBM data system will not provide this level of clinical detail and the value of the PBM data system in such instances may be to highlight cases for further analysis, which may require a reference to the patient's medical records.
A protracted admission may comprise multiple transfusion episodes. The data illustrate that in 15 and 46% of patient episodes, only one or two units of RBCs were administered. This may suggest that these units were administered to otherwise clinically stable patients. Alternatively, it may suggest that only the appropriate amount was transfused. Thus, further work to decipher the rationale for using RBCs in these instances is required. Almost half the transfusion events (47%) and transfusion admissions (46%) involved two RBC units. This may reflect that traditionally single unit RBC transfusions were viewed as poor practice, with a common misconception that two units have better outcomes than one. Numerous studies have shown that single transfusions are safe and reduce transfusion-associated morbidity and mortality, and in most instances of anaemia they will be sufficient to improve symptoms 14 . Therefore, we believe that there is vast room for improvement by clinically reviewing the requests for two units and, where appropriate, recommending them to single units.
Significantly, although the pilot hospital included an emergency department, obstetric services and surgical specialties, transfusions exceeding three units within a 24-hour time frame of the index transfusion were infrequent events, accounting for only 6% of cases.
It is perhaps noteworthy that orthopaedic and general surgery patients represented one-third of all transfusion events in this pilot hospital in the study period. In 2009-2010, there were 1.9 million separations to Australia's public and private hospitals for elective surgery. In the same period, there were 8.5 million hospital separations 2 . Thus, elective surgery accounts for nearly one-quarter of hospital separations. Understanding the drivers leading to transfusion in this cohort is therefore important. Distinguishing patients who require transfusion as a consequence of perioperative blood loss or surgical complications from anaemic patients who enter surgery offers opportunities for intervention.
The study identified the elderly as disproportionate users of RBCs. As Australia's population continues to age, understanding the reasons for this observation becomes crucial. The impact of the ageing population is further amplified when one considers that only persons aged between 18 and 70 years are eligible blood donors 15 . Further work to capture the influence of comorbidities and medications, especially anticoagulants, is required. Additionally, population surveys indicate that a significant proportion of the Australian population is anaemic 16 . Patient blood management approaches would consider diagnosis of the underlying aetiology of anaemia and conservation of the patient's red cell reserve as key considerations in the management of anaemic patients. Additionally, management of anaemia should include options such as supplemental (oral or intravenous) iron in preference to RBC transfusion 17 .
Opportunities afforded by the PBM data system
The new PBM Guidelines: Module 2-Perioperative stress the need for a nationally co-ordinated approach to data linkage and management "to facilitate a better appreciation of where blood is being used and for what purpose" 18 . We were able to link and validate a very high proportion of transfusions to their clinical events due to the presence of a patient identifier across all Western Australian metropolitan hospitals. The immense success of using a single patient identifier in linking different clinical datasets in WA should make this a 'must adopt' strategy for other states or countries wanting to create similar datasets.
The data system gave us an invaluable insight to hospital practice; it showed that the proportion of all patients receiving transfusion is small and it suggested that a handful of clinical specialties may account for the bulk of product usage. Within these specialties, specific diagnoses predominate. This picture illustrates that a targeted approach focused upon an identifiable cohort is possible. Furthermore, addressing prescribing practice in specific areas is easier and potentially more effective than a broadbrush approach targeting all clinical units within a hospital.
The data from such a system may also lend itself to future supply planning. When coupled with knowledge of population demographic changes and an understanding of clinical services to be delivered, the ability to identify key users of blood products, assess trends in usage between clinical disciplines, capture the influence of disease survivorship or population ageing, would assist in anticipating future demand for blood products.
The system can also be used to track blood usage for other organisations. Since it only makes use of hospital administrative datasets, captured by all Australian states and many of the international countries, it has the ability to be linked with any similar dataset and output the data according to the algorithms defined within the system. In situations where a unique patient identifier is not used across all sites, a single identifier can be generated first by using any of the standard linkage techniques such as "SLk 581" 19 before linking the data within the PBM system.
PBM data system as a vehicle for behavioural change
In seeking to improve prescribing practice, to better align practice with guidelines and implement a PBM program, one first needs data on current practice. The PBM data system permits this, both for the individual clinician also in relation to peers. The aim of the data system is not to assist clinicians directly in operating theatres, but to bring a positive change in clinical practice by routine feedback and reporting.
Effecting change, however, also requires clinicians and stakeholders to acknowledge the drivers for transfusion in each discipline. The rationale for transfusion in haematology patients will be distinct from that in orthopaedics. The influence of chronic anaemias and primary or secondary myelodysplasias will require further exploration as we see improved cancer survivals. Better understanding of the rationale for transfusion in orthopaedic patients may lead to discussions upon surgical technique 20 , intraoperative interventions to minimise perioperative blood loss and the identification and management of anaemias detected in the preoperative phase. Such data allows targeted interventions to implement PBM practices.
System limitations
In using the data from the PBM system, there are limitations that must be acknowledged. Retrospective data analysis presents well-described pitfalls. The price of access to all transfusion events through hospital administrative datasets is a loss of clinical detail. While one may link transfusion events to specific International Classification of Diseases or the Australian Refined Diagnosis Related Group codes, clinical oversight in interpretation remains a necessary ingredient. The high-level nature of such data results in a paucity of data regarding the clinical context surrounding the admission or transfusion event. Thus, direct comparisons must be cautioned against and care must be taken while interpreting results, as hospital administrative data alone cannot possibly report on the appropriateness of a transfusion event.
The current LIS data does not capture the details of the doctor who ordered the blood. Therefore, we had to rely on the discharging doctor to calculate blood use for clinical specialties. This might not be very accurate in specialties such as emergency medicine, where the patient is usually not admitted under an emergency physician. In an ideal world, details of the doctor who ordered blood should be available in the data.
CONCLUSION
This paper describes the effectiveness of a PBM electronic database tool in analysing, monitoring and reporting on blood utilisation and transfusion practice within a pilot hospital-based PBM program. By linking transfusion and clinical databases, we have developed a powerful tool that will facilitate more effective targeting of PBM strategies and ongoing monitoring of their impact. In addition, it could also provide opportunities for national or statewide benchmarking of practice, an exploration of the drivers leading to transfusion and a better understanding of the impact of population demographic and clinical service changes upon the supply and demand for blood products.
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